Clinical Significance of Chronic Interstitial Pneumonia Induced by EGFR-TKI Administration

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has demonstrated impressive efficacy as a first-line treatment for patients with advanced EGFR mutation-positive lung cancer. Drug-related pneumonitis (DRP) is a lethal complication of EGFR-TKI treatment. Clinically, some patients exhibit chronic progression of interstitial pneumonia. However, there are no reports on the precise prevalence, disease course, and safety of EGFR-TKI continuation.